Hepatitis A vaccine liposomal - Crucell

Drug Profile

Hepatitis A vaccine liposomal - Crucell

Alternative Names: Epaxal; Epaxal Junior; HAVpur; HAVpur Junior; IRIV-hepatitis A vaccine; Virohep-A; Virohep-A Junior

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Berna Biotech
  • Developer Crucell; GlaxoSmithKline
  • Class Hepatitis A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis A

Most Recent Events

  • 28 Feb 2011 Crucell completed enrolment in a phase III, long-term follow-up trial for Hepatitis A (Prevention, In infants) in Israel (NCT01307436)
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 01 Jan 2010 Registered for Hepatitis A in Israel (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top